Results of a Phase 2 Study of the Oxyntomodulin (OXM) Analogue LY2944876 in Patients with Type 2 Diabetes (T2DM)

Sheetz, M; Bray, R; Tham, LS; Jones, C; Kinsella, J; Violante-Ortiz, R

DIABETES, 2017; 66 ( ): A282